PharmaCom BioVet, Inc. and IsoTherapeutics Group, LLC Announces Liquid Brachytherapy Planned for Canine Cancer Treatment Centers
October 21 2008 - 8:30AM
Marketwired
PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce
its plans with IsoTherapeutics Group, LLC to explore the latest
ground-breaking direct injection liquid brachytherapy therapeutic
radioisotope procedures* for use within its canine cancer treatment
centers.
As part of its plans for state-of-the-art treatment centers for
canine lymphoma and other forms of cancer, PharmaCom BioVet, Inc.
is greatly encouraged by the latest research results in direct
injection of liquid brachytherapy radioisotopes into tumors.
Recently published collaborate studies on canines and mice by
IsoTherapeutics Group, LLC and Valco Instruments Company Inc. have
demonstrated that direct injection procedures with an easy to
prepare, high pH formulation allow for better targeting of the
radioisotope treatment with less migration into other non-cancerous
cells.
Recent advances in cancer treatments such as these are
fundamental to the scientific basis for PharmaCom BioVet, Inc.
"Part of our commitment is to support and harness these
cutting-edge methodologies for both cancer treatment and
prevention," asserts Gary S. Berthold, Founder and President/CEO of
PharmaCom BioVet, Inc. "The meaningful research with liquid
brachytherapy direct injections provides new hope for companion
animal lovers and adds to the substantive treatment options
portfolio within our new cancer treatment centers," Berthold
added.
Berthold also stated, "While researching treatment options for
our own pets, we discovered a dynamic convergence within the
veterinary and cancer research industries towards providing new
treatment technologies for companion animals suffering from cancer.
We also discovered a significant and growing demand for companion
animal cancer care, and simultaneously found that there are almost
no facilities dedicated to developing and providing these new
treatment programs. Based on these factors, we decided to dedicate
our lives to creating canine cancer treatment centers around the
country," Berthold concluded.
About PharmaCom BioVet, Inc.:
PharmaCom BioVet, Inc. seeks to further the opportunities
available to people who have encountered cancer in their companion
animals and to offer their animals a better quality of life and
longevity. PharmaCom BioVet, Inc. is dedicated to advancing the
veterinary care industry for companion animals by establishing
state-of-the-art treatment centers for lymphoma and other forms of
cancer throughout the country. The purpose of these centers is to
help prolong the quality of life for companion animals with cancer
and pursue the potential for complete cure. These centers will also
operate under the philosophy of providing a compassionate care
environment for both companion animal patients and their owners.
For more information, please visit our website
www.PharmaComBioVet.com.
About IsoTherapeutics Group, LLC:
The mission of IsoTherapeutics Group, LLC is to develop novel
diagnostic and therapeutic agents for the treatment of severe
diseases. ITG develops both proprietary technologies as well as
partners with other companies to help develop pharmaceuticals. Of
special interest are radiopharmaceuticals for oncology. In house
expertise includes synthetic organic chemistry, chelation
chemistry, radiochemistry, diagnostic and therapeutic isotopes,
conjugation chemistry, pharmacokinetics, and small animal research
models. For more information, please visit our website
www.isotherapeutics.com.
DISCLOSURE:
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995: This press release contains forward-looking
statements that are subject to risk and uncertainties, including,
but not limited to, the impact of competitive products, product
demand, market acceptance risks, fluctuations in operating results,
political risk and other risks detailed from time to time in
PharmaCom BioVet, Inc.'s filings with the Securities and Exchange
Commission. These risks could cause PharmaCom BioVet, Inc.'s actual
results to differ materially from those expressed in any
forward-looking statements made by, or on behalf of, PharmaCom
BioVet, Inc.
*Reference: Jim Simon, Kenneth McMillan, Keith Frank of
IsoTherapeutics Group LLC, Angleton, Texas. Stan Stearns, Max Loy
of Valco Instruments Co. Inc., Houston, Texas
Contact: Market Ideas, Inc. 877-295-3981 ext. 2
info@marketideasinc.com
PharmaCom BioVet (CE) (USOTC:PHMB)
Historical Stock Chart
From Apr 2024 to May 2024
PharmaCom BioVet (CE) (USOTC:PHMB)
Historical Stock Chart
From May 2023 to May 2024